COAG - Latest News

Hemab Therapeutics Holdings, Inc. Common Stock (COAG), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $87.0M. Beta to the broader market is 0.00.

The article list below shows the most recent COAG headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent COAG Headlines

Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts

seekingalpha.com - Jul 15, 2026

Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COA

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

globenewswire.com - Jul 14, 2026

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H

Hemab Advances Bleeding Disorder Pipeline

benzinga.com - Jul 13, 2026

Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introd

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

globenewswire.com - Jul 12, 2026

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

globenewswire.com - Jun 26, 2026

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Fa

How News Affects COAG Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track COAG's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked COAG news questions

What is the latest COAG news headline?

The most recent COAG headline (Jul 15, 2026) is "Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the COAG news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What COAG news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual COAG options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.